menu
    • menu
    [{"orgOrder":0,"company":"Xiling Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SMP-100","moa":"5-HT3 receptor","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Xiling Lab","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Xiling Lab \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Xiling Lab \/ Undisclosed"},{"orgOrder":0,"company":"Xiling Lab","sponsor":"Kexing Biopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Xiling Lab","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xiling Lab \/ Kexing Biopharm","highestDevelopmentStatusID":"15","companyTruncated":"Xiling Lab \/ Kexing Biopharm"}]

    Find Clinical Drug Pipeline Developments & Deals by Xiling Lab

    Menu

    Xiling Lab

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Xiling Lab

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Xiling Lab

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eribulin

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Kexing Biopharm

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kexing Introduces Eribulin Mesylate Injection, Expanding Overseas Product Offerings

                            Details : Under the agreement, Kexing licenses Eribulin Mesylate Injection, indicated for patients with locally advanced or metastatic breast cancer, from Xiling Lab

                            Product Name : Eribulin Mesylate-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 05, 2024

                            Lead Product(s) : Eribulin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Kexing Biopharm

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Xiling Lab

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Xiling Lab

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SMP-100

                            Therapeutic Area : Gastroenterology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Scimount Announces FDA Approval of SMP-100's IND Application for the Treatment of Irritable Bowel Syndrome

                            Details : First randomized, double-blinded, placebo-controlled Phase I clinical trial to investigate the safety and pharmacokinetics after oral administration of SMP-100 in healthy volunteers.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 14, 2020

                            Lead Product(s) : SMP-100

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth